Dietary Practices and Locally Advanced Lung Cancer (LUNGDIET)

Assistance Publique - Hôpitaux de Paris

Status

Not yet enrolling

Conditions

Carcinoma, Non-Small-Cell Lung

Treatments

Behavioral: Self-administered survey at hospital

Other: Consultation with nutritionist doctor and dietician

Biological: Blood sample for nutritional assessment

Study type

Observational

Funder types

Other

Identifiers

NCT06068088

IDRCB 2023-A00329-36 (Other Identifier)

23.01988.000202 (Other Identifier)

APHP230706

Details and patient eligibility

About

In recent years, fasting or the use of special diets (ketogenic, high protein, etc.), whether or not associated with food supplements, have increased substantially, particularly in oncology with the idea of improving for some of them, the tolerance of the proposed treatments, in particular emetogenic chemotherapy, or even to improve the prognosis. Although there are preclinical data on cell cultures and in rats, the clinical data supporting these practices are very fragmented, with few trials carried out and only including small cohorts, mainly in the context of breast cancers. It is therefore very difficult to respond objectively to patients asking the question of the merits of these changes in dietary practices in the management of their cancer.

The investigators want to carry out an inventory of the dietary practices of participating patients and their potential interest in fasting or special diets by means of a self-administered survey completed by the patient at diagnosis before treatment. This semi-quantitative self-administered survey (answers in never / sometimes / regularly / systematically) was developed by the nutrition and radiotherapy team of the Georges-Pompidou European Hospital because there was no validated medical questionnaire on fasting or the use of special diets in oncology

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically documented inoperable stage III non-small cell lung carcinoma (no metastasis)
Treatment with curative intent including thoracic radiotherapy and at least one cycle of concomitant chemotherapy
Patient informed and having signed the consent

Exclusion criteria

Sequential radiochemotherapy
Metastatic forms from the outset
Ear, nose, and throat (ENT) or digestive pathologies interfering with normal oral nutrition
Other concurrent or pre-existing cancer for less than 5 years at the diagnosis of bronchial cancer
Patient under guardianship or curatorship
Patient with cognitive impairment
Patient not affiliated with a social security
Patient under state medical help from french government
Radiotherapy performed outside the AP-HP for cohort A and outside the HEGP for cohort B